Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.

Cost of Revenue Trends: GSK vs. BioMarin (2014-2023)

__timestamp	BioMarin Pharmaceutical Inc.	GSK plc
Wednesday, January 1, 2014	129764000	7323000000
Thursday, January 1, 2015	152008000	8853000000
Friday, January 1, 2016	209620000	9290000000
Sunday, January 1, 2017	241786000	10342000000
Monday, January 1, 2018	315264000	10241000000
Tuesday, January 1, 2019	359466000	11863000000
Wednesday, January 1, 2020	524272000	11704000000
Friday, January 1, 2021	470515000	11603000000
Saturday, January 1, 2022	483669000	9554000000
Sunday, January 1, 2023	577065000	8565000000
Monday, January 1, 2024	580235000

In pursuit of knowledge

Analyzing Cost of Revenue: GSK plc vs. BioMarin Pharmaceutical Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for GSK plc and BioMarin Pharmaceutical Inc. from 2014 to 2023. Over this period, GSK plc consistently reported a higher cost of revenue, peaking in 2019 with a 62% increase from 2014. In contrast, BioMarin Pharmaceutical Inc. showed a more dynamic growth, with a staggering 345% rise in cost of revenue by 2023. This trend reflects BioMarin's aggressive expansion and investment in research and development. Meanwhile, GSK's cost fluctuations suggest strategic shifts in its operational focus. As the pharmaceutical landscape continues to change, these insights provide a window into the financial strategies of two industry giants.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025